Skip to main content

Avanos Medical, Inc. (AVNS)

NYSE: AVNS · IEX Real-Time Price · USD
32.88 -0.04 (-0.12%)
Sep 20, 2021 2:07 PM EDT - Market open
Market Cap1.58B
Revenue (ttm)737.80M
Net Income (ttm)2.40M
Shares Out48.07M
EPS (ttm)0.04
PE Ratio822.00
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume148,668
Open32.29
Previous Close32.92
Day's Range32.41 - 32.94
52-Week Range30.96 - 53.61
Beta0.91
AnalystsBuy
Price Target43.00 (+30.8%)
Est. Earnings DateNov 2, 2021

About AVNS

Avanos Medical, Inc. operates as a medical technology company that focuses on delivering medical device solutions to improve patients' quality of life in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management...

IndustryHealth Care Equipment & Supplies
CEOJoseph Woody
Employees5,380
Stock ExchangeNYSE
Ticker SymbolAVNS
Full Company Profile

Financial Performance

In 2020, Avanos Medical's revenue was $714.80 million, an increase of 2.47% compared to the previous year's $697.60 million. Losses were -$27.20 million, -40.74% less than in 2019.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for Avanos Medical stock is "Buy." The 12-month stock price forecast is 43.00, which is an increase of 30.78% from the latest price.

Price Target
$43.00
(30.78% upside)
Analyst Consensus: Buy

News

Why Is Avanos Medical (AVNS) Down 2.2% Since Last Earnings Report?

Avanos Medical (AVNS) reported earnings 30 days ago. What's next for the stock?

2 weeks ago - Zacks Investment Research

Avanos Medical (AVNS) Q2 Earnings Lag Estimates, Revenues Top

Avanos Medical's (AVNS) second-quarter 2021 results gains from strength in Pain Management segment.

1 month ago - Zacks Investment Research

Avanos Medical Shares Fall As Higher Transportation Costs Hit Q2 Margins; Lowers FY21 Guidance

Avanos Medical Inc (NYSE: AVNS) reported a second-quarter FY21 adjusted EPS of $0.21, missing the consensus of $0.23. The sales of $186.4 million increased 14% Y/Y, beating the analyst estimate of $180....

1 month ago - Benzinga

Avanos Medical (AVNS) Q2 Earnings Miss Estimates

Avanos Medical (AVNS) delivered earnings and revenue surprises of -8.70% and 2.36%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Avanos Medical: Q2 Earnings Insights

Shares of Avanos Medical (NYSE:AVNS) remained unaffected after the company reported Q2 results. Quarterly Results Earnings per share rose 61.54% year over year to $0.21, which missed the estimate of $0.23.

1 month ago - Benzinga

Avanos Medical, Inc. Announces Second Quarter 2021 Results

ALPHARETTA, Ga., Aug. 3, 2021 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today reported second quarter 2021 financial results.

1 month ago - PRNewsWire

Avanos Medical (AVNS) Earnings Expected to Grow: Should You Buy?

Avanos Medical (AVNS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Will Avanos Medical (AVNS) Beat Estimates Again in Its Next Earnings Report?

Avanos Medical (AVNS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

1 month ago - Zacks Investment Research

Avanos Medical, Inc. To Webcast Conference Call Discussing Second Quarter 2021 Financial Results

ALPHARETTA, Ga., July 27, 2021 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) will webcast its conference call discussing financial results and business highlights for the second quarter 2021 on Tues...

1 month ago - PRNewsWire

Here's Why You Should Retain Avanos (AVNS) Stock for Now

Investors continue to be optimistic about Avanos (AVNS) owing to its strong product line and focus on R&D.

2 months ago - Zacks Investment Research

Avanos Medical, Inc. Appoints Moji James as Senior Vice President & General Counsel

ALPHARETTA, Ga., July 12, 2021 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced that Moji James has been appointed senior vice president & general counsel.

2 months ago - PRNewsWire

Avanos Medical, Inc. to Present at the 2021 Raymond James Human Health Innovation Conference

ALPHARETTA, Ga., June 18, 2021 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced that Joe Woody, chief executive officer, will present and participate in an analyst-led fireside chat at ...

3 months ago - PRNewsWire

Here's Why You Should Hold on to Avanos (AVNS) Stock for Now

Investors continue to be optimistic about Avanos (AVNS), owing to its strong product line and focus on its R&D.

4 months ago - Zacks Investment Research

Charles River Laboratories International Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

NEW YORK, May 10, 2021 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600: S&P MidCap 400 constituent Charles River Laboratories I...

Other symbols:CRLEFCNSASPGITDY
4 months ago - PRNewsWire

Avanos Medical (AVNS) Q1 Earnings and Revenues Top Estimates

Avanos Medical (AVNS) continues to gain from its core Chronic Care segment in the first quarter.

4 months ago - Zacks Investment Research

Avanos Medical (AVNS) Beats Q1 Earnings and Revenue Estimates

Avanos Medical (AVNS) delivered earnings and revenue surprises of 27.78% and 2.30%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Avanos Medical, Inc. Announces First Quarter 2021 Results

ALPHARETTA, Ga., May 7, 2021 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today reported first quarter 2021 financial results.

4 months ago - PRNewsWire

Avanos Medical, Inc. To Webcast Conference Call Discussing First Quarter 2021 Financial Results

ALPHARETTA, Ga., April 30, 2021 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) will webcast its conference call discussing financial results and business highlights for the first quarter 2021 on Frid...

4 months ago - PRNewsWire

Avanos Medical (AVNS) Earnings Expected to Grow: Should You Buy?

Avanos Medical (AVNS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

Avanos Medical (AVNS) Down 1% Since Last Earnings Report: Can It Rebound?

Avanos Medical (AVNS) reported earnings 30 days ago. What's next for the stock?

6 months ago - Zacks Investment Research

Avanos Medical, Inc. to Present at the KeyBanc Life Sciences & MedTech Investor Forum

ALPHARETTA, Ga., March 16, 2021 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced that Joe Woody, chief executive officer, will present at the Virtual KeyBanc Life Sciences & MedTech Inv...

6 months ago - PRNewsWire

Here's Why You Should Retain Avanos Medical (AVNS) Stock Now

Investor confidence is high in Avanos Medical (AVNS) stock, courtesy of its solid prospects.

6 months ago - Zacks Investment Research

Avanos Medical, Inc. to Present at the Virtual Raymond James 42nd Annual Institutional Investors Conference

ALPHARETTA, Ga., Feb. 24, 2021 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced that Michael Greiner, senior vice president and chief financial officer, will present at the Virtual Raym...

6 months ago - PRNewsWire

Avanos Medical (AVNS) Q4 Earnings and Revenues Top Estimates

Avanos Medical (AVNS) continues to gain from its core Chronic Care segment in the fourth quarter.

7 months ago - Zacks Investment Research

Avanos Medical (AVNS) Tops Q4 Earnings and Revenue Estimates

Avanos Medical (AVNS) delivered earnings and revenue surprises of 27.27% and 0.67%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research